Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

This study has been terminated.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: August 30, 2011
Last updated: April 1, 2014
Last verified: June 2013
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: No date given
  Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)